Completed

Atenolol Exposure as Risk for Adverse Metabolic Responses to Beta Blockers

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Glucose

Other
Who is being recruted

Cardiovascular Diseases+4

+ Hypertension

+ Metabolic Diseases

From 18 to 65 Years
+4 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Prevention Study

Interventional
Study Start: February 2008
See protocol details

Summary

Principal SponsorUniversity of Florida
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: February 1, 2008

Actual date on which the first participant was enrolled.

The current study is a sub-study of Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR - NCT00246519). The primary objective of this pharmacokinetic (PK) study is to investigate the correlation of atenolol Cp with hypertriglyceridemia and insulin sensitivity in mild to moderate hypertensive patients after 6-8 weeks of atenolol treatment. Participants will undergo the PK study when they have been on atenolol 100 mg once daily for at least 4 weeks and on atenolol therapy (50 mg or 100 mg) for ≥ 7 weeks. They will undergo a two hour Oral Glucose Tolerance Test (OGTT), 1 hour after atenolol dosing. Blood will be drawn at 12 time points for 24 hours. Atenolol Cp will be measured in all 12 blood samples and will be correlated with the glucose/insulin measured during the OGTT.

Official TitleAtenolol Exposure as Risk for Adverse Metabolic Responses to Beta Blockers
NCT00607347
Principal SponsorUniversity of Florida
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

24 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Prevention Study

Prevention studies aim to stop a disease from developing. They often involve people at risk and test things like vaccines, lifestyle changes, or preventive medications.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 65 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Cardiovascular DiseasesHypertensionMetabolic DiseasesNutritional and Metabolic DiseasesVascular DiseasesDyslipidemiasLipid Metabolism Disorders

Criteria

2 inclusion criteria required to participate
Subjects from PEAR who are on atenolol 100 mg once daily will be invited to participate
Other inclusion criteria from PEAR
2 exclusion criteria prevent from participating
Patients with BMI >35 kg/m2 will be excluded
Other exclusion criteria from PEAR

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
The subjects will be undergoing a oral glucose tolerance test.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

University of Florida

Gainesville, United StatesOpen University of Florida in Google Maps
CompletedOne Study Center